REFERENCES

• American Psychiatrie Association Practice Guidelines. Practice guideline for the treatment of patients with major depressive disorder (revision).Am J Psychiatry.2000157(suppl 4)145
   Google Scholar
• BauerM.WhybrowPC.AngstJ.VersianiM.MöIIerHJ.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 1: acute and continuation treatment of major depressive disorder.World J Biol Psychiatry.2002354312479086
   PubMedGoogle Scholar
• DonoghueJ.TaylorDM.Suboptimal use of antidepressants in the treatment of depression.CNS Drugs.200013365383
   Web of Science ®Google Scholar
• HirschfeldRMA.MontgomerySA.AgugliaE.et al.Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.J Clin Psychiatry.20026382683712363125
   PubMed Web of Science ®Google Scholar
• OlverJS.BurrowsGD.NormanTR.Third-generation antidepressants―do they offer advantages over the SSRls?CNS Drugs.20011594195411735614
   PubMed Web of Science ®Google Scholar
• NelsonJC.Augmentation strategies in depression 2000.J Clin Psychiatry.200061 (suppl2)131910714619
   PubMed Web of Science ®Google Scholar
• ZullinoD.BaumannP.Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors.Pharmacopsychiatry.20013411912711518471
   PubMed Web of Science ®Google Scholar
• StimpsonN.AgrawalN.LewisG.Randomised controlled trials investigating pharmacological and psychological interventions for treatmentrefractory depression.Br J Psychiatry.200218128429412356654
   PubMed Web of Science ®Google Scholar
• ThaseME.The need for clinically relevant research on treatment-resistant depression.J Clin Psychiatry20016222122411379833
   PubMed Web of Science ®Google Scholar
• MichelsonD.AllenAJ.BusnerJ.et al.Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.Am J Psychiatry.20021591896190112411225
   PubMed Web of Science ®Google Scholar
• BaumannP.HiemkeC.UlrichS.et al.The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.Pharmacopsychiatry20043724326515551191
   PubMed Web of Science ®Google Scholar
• ÅsbergM.CronholmB.SjöqvistF.TuckD.Relationship between plasma level and therapeutic effect of nortriptyline.BMJ.197133313345558186
   PubMed Web of Science ®Google Scholar
• BertilssonL.MellströmB.SjöqvistF.MårtenssonB.ÅsbergM.Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.Lancet.1981i5605616111662
   PubMedGoogle Scholar
• TaskForce.Tricyclic antidepressants―blood level measurements and clinical outcome: an APATask Force report.Am J Psychiatry.19851421551623881999
   PubMed Web of Science ®Google Scholar
• OrsulakPJ.Therapeutic monitoring of antidepressant drugs―guidelines updated.Ther Drug Monit.1989114975072683251
   PubMed Web of Science ®Google Scholar
• LinderMW.KeckPE.Jr.Standards of laboratory practice: antidepressant drug monitoring.Clin Chem.199844107310849590392
   PubMed Web of Science ®Google Scholar
• LauxG.RiedererP (eds).XX.Plasmaspiegel-bestimmung von Psychopharmaka: Therapeutisches Drug―Monitoring Versuch einer ersten Standortbestimmung. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH;1992XXXXXX
   Google Scholar
• KirchheinerJ.BrøsenK.DahlML.et al.CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.Acta Psychiatr Scand.200110417319211531654
   PubMed Web of Science ®Google Scholar
• DahlML.Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?Clin Pharmacokinet.20024145347012083975
   PubMed Web of Science ®Google Scholar
• UlrichS.WurthmannC.BroszM.MeyerFP.The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.Clin Pharmacokinet.1998342272639533984
   PubMed Web of Science ®Google Scholar
• HiemkeC.HärtterS.Pharmacokinetics of selective serotonin reuptake inhibitors.Pharmacol Ther.200085112810674711
   PubMed Web of Science ®Google Scholar
• GreenblattDJ.Von MoltkeLL.HarmatzJS.ShaderRl.Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.J Clin Psychopharmacol.199919(suppl 1)23S35S10507506
   PubMed Web of Science ®Google Scholar
• NemeroffCB.DeVaneCL.PollockBG.Newer antidepressants and the cytochrome P450 system.Am J Psychiatry.19961533113208610817
   PubMed Web of Science ®Google Scholar
• MeyerUA.AmreinR.BalantLP.et al.Antidepressants and drug-metabolizing enzymes―expert group report.Acta Psychiatr Scand.19969371798686486
   PubMed Web of Science ®Google Scholar
• RudorferMV.PotterWZ.Metabolism of tricyclic antidepressants.Cell Mol Neurobiol.19991937340910319193
   PubMed Web of Science ®Google Scholar
• Breyer-PfaffU.GaertnerHJ.BaumannP.XX.Antidepressiva―Pharmakologie, therapeutischer Einsatz und Klinik der Depressionen. 2nd ed. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH;2005XXXXXX
   Google Scholar
• MarzoA.BalantLP.Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods.J Chromatogr B Biomed Appl.199667873928861658
   PubMed Web of Science ®Google Scholar
• BaumannP.ZullinoDF.EapCB.Enantiomers' potential in psychopharmacology―a critical analysis with special emphasis on the antidepressant escitalopram.Eur Neuropsychopharmacol.20021243344412208561
   PubMed Web of Science ®Google Scholar
• TestaB.Drug metabolism. In: Wolff ME, ed.Burger's Medicinal Chemistry and Drug Discovery. 5th ed. New York, NY: John Wiley and Sons;1995XX129180
   Google Scholar
• ListonHL.MarkowitzJS.DeVaneCL.Drug glucuronidation in clinical psychopharmacology.J Clin Psychopharmacol.20012150051511593076
   PubMed Web of Science ®Google Scholar
• BurchellB.Transformation reactions: glucuronidation. In: Woolf TF, ed.Handbook of Drug Metabolism. New York, NY: Marcel Dekker;1999XX153173
   Google Scholar
• PenzakSR.HonYY.LawhornWD.ShirleyKL.SpratlinV.JannMW.Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.J Clin Psychopharmacol.20022236637012172335
   PubMed Web of Science ®Google Scholar
• CacciaS.GarattiniS.Formation of active metabolites of psychotropic drugs: an updated review of their significance.Clin Pharmacokinet.1990184344592191820
   PubMed Web of Science ®Google Scholar
• EadieMJ.Formation of active metabolites of anticonvulsant drugs―a review of their pharmacokinetic and therapeutic significance.Clin Pharmacokinet19912127411914340
   PubMed Web of Science ®Google Scholar
• RudorferMV.PotterWZ.The role of metabolites of antidepressants in the treatment of depression.CNS Drugs.19977273312
   PubMed Web of Science ®Google Scholar
• BertilssonL.DahlML.DalenP.AI ShurbajiA.Molecular genetics of CYP 2D6: clinical relevance with focus on psychotropic drugs.Br J Clin Pharmacol.20025311112211851634
   PubMed Web of Science ®Google Scholar
• CascorbiI.Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication.Eur J Clin invest.200333(suppl 2)172214641552
   PubMed Web of Science ®Google Scholar
• MurrayM.P450 Enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.Clin Pharmacokinet.1992231321461511529
   PubMed Web of Science ®Google Scholar
• DahlML.SjöqvistF.Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.Ther Drug Monit.20002211411710688272
   PubMed Web of Science ®Google Scholar
• KirchheinerJ.NickchenK.BauerM.et al.Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.Mol Psychiatry.2004944247315037866
   PubMed Web of Science ®Google Scholar
• VasiliouV.PappaA.PetersenDR.Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism.Chem Biol Interact.200012911911154732
   PubMed Web of Science ®Google Scholar
• CouttsRT.UrichukLJ.Polymorphic cytochromes P450 and drugs used in psychiatry.Cell Mol Neurobiol.19991932535410319191
   PubMed Web of Science ®Google Scholar
• BenetLZ.KroetzDL.SheinerLB.Pharmacokinetics the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, eds.Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill;1996XX327
   Google Scholar
• ScordoMG.SpinaE.Cytochrome P450 polymorphisms and response to antipsychotic therapy.Pharmacogenomics.2002320121811972442
   PubMed Web of Science ®Google Scholar
• KuehlP.ZhangJ.LinY.et al.Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.Nat Genet.20012738339111279519
   PubMed Web of Science ®Google Scholar
• NakajimaM.YokoiT.MizutaniM.KinoshitaM.FunayamaM.KamatakiT.Genetic polymorphism in the 5'-fIanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.J Biochem.199912580380810101295
   PubMed Web of Science ®Google Scholar
• SachseC.BrockmöIIerJ.BauerS.RootsI.Functional significance of a C_A polymorphism in intron I of the cytochrome P450 CYP 1A2 gene tested with caffeine.Br J Clin Pharmacol.19994744544910233211
   PubMed Web of Science ®Google Scholar
• BrøsenK.Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry.Ther Drug Monit.1996183933968857557
   PubMed Web of Science ®Google Scholar
• DeVaneCL.Pharmacogenetics and drug metabolism of newer antidepressant agents.J Clin Psychia try.199455(suppl 12)3845
   Web of Science ®Google Scholar
• OtaniK.AoshimaT.Pharmacogenetics of classical and new antipsychotic drugs.Ther Drug Monit.20002211812110688273
   PubMed Web of Science ®Google Scholar
• SteimerW.PotterJM.Pharmacogenetic screening and therapeutic drugs.Clin ChimActa.2002315137155
   PubMed Web of Science ®Google Scholar
• KirchheinerJ.BertilssonL.BruusH.WolffA.RootsI.BauerM.Individualized medicine―implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.Pharmacopsychiatry.200336(suppl 3)S235S24314677085
   PubMed Web of Science ®Google Scholar
• EapCB.Jaquenoud SirotE.BaumannP.Therapeutic monitoring of antidepressants in era of pharmacogenetics studies.Ther Drug Monit.20042615215515228156
   PubMed Web of Science ®Google Scholar
• De LeonJ.Glucuronidation enzymes, genes and psychiatry.Int J Neuropsychopharmacol.20036577212899737
   PubMed Web of Science ®Google Scholar
• MarzoliniC.PausE.BuclinT.KimRB.Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.Clin Pharmacol Ther.200475133314749689
   PubMed Web of Science ®Google Scholar
• UhrM.GrauerMT.abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.J Psychiatr Res.20033717918512650738
   PubMed Web of Science ®Google Scholar
• UhrM.StecklerT.YassouridisA.HolsboerF.Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption.Neuropsychopharmacology.20002238038710700657
   PubMed Web of Science ®Google Scholar
• PerryPJ.The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis.Clin Pharmacokinet.1987133813923325215
   PubMed Web of Science ®Google Scholar
• PerryPJ.ZeilmannC.ArndtS.Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response.J Clin Psychopharmacol.1994142302407962678
   PubMed Web of Science ®Google Scholar
• UlrichS.LäuterJ.Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression.Clin Pharmacokinet.20024185387612190332
   PubMed Web of Science ®Google Scholar
• Balant-GorgiaEA.BalantLP.Therapeutic drug monitoring―relevance during the drug treatment of psychiatric disorders.CNS Drugs.19954432453
   Web of Science ®Google Scholar
• EilersR.Therapeutic drug monitoring for the treatment of psychiatric disorders―clinical use and cost effectiveness.Clin Pharmacokinet.1995294424508787949
   PubMed Web of Science ®Google Scholar
• GreenM.A practical guide to analytical method validation.Anal Chem News Features.1996XX305309
   Google Scholar
• BuickAR.DoigMV.JealSC.LandGS.McdowallRD.Method validation in the bioanalytical laboratory.J Pharm Biomed Anal.199086296372100599
   PubMed Web of Science ®Google Scholar
• ShahVP.MidhaKK.DigheS.et al.Analytical methods validation―bioavailability, bioequivalence and pharmacokinetic studies.Pharm Res.19929588592
   Web of Science ®Google Scholar
• CausonR.Validation of chromatographic methods in biomedical analysis viewpoint and discussion.J Chromatogr B.1997689175180
   PubMed Web of Science ®Google Scholar
• de la TorreR.OrtuñoJ.PascualJA.GonzalezS.BallestaJ.Quantitative determination of tricyclic antidepressants and their metabolites in plasma by solid-phase extraction (bond-elute TCA) and separation by capillary gas chromatography with nitrogen-phosphorus detection.Ther Drug Monit.1998203403469631934
   PubMed Web of Science ®Google Scholar
• BangerM.HermesB.HärtterS.HiemkeC.Monitoring serum concentrations of clomipramine and metabolites: fluorescence polarization immunoassay versus high performance liquid chromatography.Pharmacopsychiatry.1997301281329271779
   PubMed Web of Science ®Google Scholar
• KoIIroserM.SchoberC.Simultaneous determination of seven tricyclic antidepressant drugs in human plasma by direct-injection HPLC-APCI-MSMS with an ion trap detector.Ther Drug Monit.20022453754412142640
   PubMed Web of Science ®Google Scholar
• VeutheyJL.SouverainS.RudazS.Column-switching procedures for the analysis of drugs in biologic samples.Ther Drug Monit.20042616116615228158
   PubMed Web of Science ®Google Scholar
• SimmonsSA.PerryPJ.RickertED.BrowneJL.Cost-benefit analysis of prospective pharmocokinetic dosing of nortriptyline in depressed inpatients.J Affect Disord.1985847533156911
   PubMed Web of Science ®Google Scholar
• LundmarkJ.BengtssonF.NordinC.ReisM.WalinderJ.Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients.Acta Psychiatr Scand.200010135435910823294
   PubMed Web of Science ®Google Scholar
• MüllerMJ.DragicevicA.FricM.et al.Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?Pharmacopsychiatry.2003369810412806567
   PubMed Web of Science ®Google Scholar
• ChenS.ChouWH.BlouinRA.et al.The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.Clin Pharmacol Ther.1996605225348941025
   PubMed Web of Science ®Google Scholar
• ChouWH.YanFX.BarnhillJ.et al.Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.J Clin Psychopharmacol.20002024625110770465
   PubMed Web of Science ®Google Scholar
• VeenstraDL.HigashiMK.Assessing the cost-effectiveness of pharmacogenomics.AAPS Pharmsci.20002111
   Google Scholar
• BaumannP.Jonzier-PereyM.KoebL.LePK.TinguelyD.SchöpfJ.Amitriptyline pharmacokinetics and clinical response. I. Free and total plasma amitriptyline and nortriptyline.Int Clin Psychopharmacol.19861891013571944
   PubMed Web of Science ®Google Scholar
• JungkunzG.KussHJ.On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline-treated depressive patients.Pharmakopsychiatr Neuropsychopharmakol.1980131111167393997
   PubMedGoogle Scholar
• Breyer-PfaffU.GaertnerHJ.KreuterF.ScharekG.BrinkschulteM.WiatrR.Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels.Psychopharmacology.1982762402446808544
   PubMed Web of Science ®Google Scholar
• Breyer-PfaffU.GaertnerHJ.GiedkeH.Plasma levels, psychophysiological variables, and clinical response to amitriptyline.Psychiatry Res.198262232346953461
   PubMed Web of Science ®Google Scholar
• KupferDJ.HaninI.SpikerDG.GrauT.CobleP.Amitriptyline plasma levels and clinical response in primary depression.Clin Pharmacol Ther.197722904911923185
   PubMed Web of Science ®Google Scholar
• BaumannP.NilR.SoucheA.et al.A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.J Clin Psychopharmacol.1996163073148835706
   PubMed Web of Science ®Google Scholar
• BaumannP.NilR.BertschyG.et al.A double-blind double-dummy study of citalopram comparing infusion versus oral administration.J Affect Disord.1998492032109629950
   PubMed Web of Science ®Google Scholar
• Kramer NielsenK.BrøsenK.GramLF.et al.Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism.Eur J Clin Pharmacol.1992434054111451721
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics.Clin Pharmacol Ther.19996615216510460069
   PubMed Web of Science ®Google Scholar
• Müller-OerlinghausenB.FahndrichE.The relationship between pharmacokinetic data and the clinical response in patients treated with maprotiline or clomipramine by intravenous infusion.Pharmacopsychiatry.200218100101
   Google Scholar
• BurchJE.RaddatsMA.Time course of plasma drug levels during once-daily oral administration of clomipramine.Psychopharmacology.1982773443476813895
   PubMed Web of Science ®Google Scholar
• FriedelRO.VeithRC.BloomV.BielskiRJ.Desipramine plasma levels and cliical response in depressed outpatients.Commun Psychopharmacol.197938187380887
   PubMedGoogle Scholar
• AmsterdamJD.BrunswickDJ.WinokurA.RickelsK.Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients.Arch Gen Psychiatry.1985423613643977553
   PubMed Web of Science ®Google Scholar
• NelsonJC.JatlowPI.MazureC.Desipramine plasma levels and response in elderly melancholic patients.J Clin Psychopharmacol.198552172204019810
   PubMed Web of Science ®Google Scholar
• MaguireKP.NormanTR.BurrowsGD.DaviesB.Blood and plasma concentrations of dothiepin and its major metabolites and clinical response.J Affect Disord.1982441486461686
   PubMed Web of Science ®Google Scholar
• IlettKF.BIytheTH.HackettLP.OngRTT.TannenbaumDA.ClarkeTMF.Plasma concentrations of dothiepin and its metabolites are not correlated with clinical efficacy in major depressive illness.Ther Drug Monit.1993153513578249040
   PubMed Web of Science ®Google Scholar
• AdlerL.HajakG.LehmannK.et al.On the problems of switching from intravenous to oral administration in drug treatment of endogenous depression―a placebo-controlled double-blind trial with doxepin.Pharmacopsychiatry.19973062699131726
   PubMed Web of Science ®Google Scholar
• DeuschleM.HärtterS.HiemkeC.StandhardtH.HeuserI.Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients.Psychopharmacology.199713119229181631
   PubMed Web of Science ®Google Scholar
• LeuchtS.SteimerW.KreuzS.AbrahamD.OrsuiakPJ.KisslingW.Doxepin plasma concentrations: is there really a therapeutic range?J Clin Psychopharmacol.20012143243911476128
   PubMed Web of Science ®Google Scholar
• BondolfïG.ChautemsC.RochatB.BertschyG.BaumannP.Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.Psychopharmacology.19961284214258986013
   PubMed Web of Science ®Google Scholar
• BondolfïG.LissnerC.KoselM.EapCB.BaumannP.Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences.Int J Neuropsychopharmacol.20003556011343579
   PubMed Web of Science ®Google Scholar
• LundmarkJ.ReisM.BengtssonF.Serum concentrations of fluoxetine in the clinical treatment setting.Ther Drug Monit.20012313914711294514
   PubMed Web of Science ®Google Scholar
• AmsterdamJD.FawcettJ.QuitkinFM.et al.Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.Am J Psychiatry.19971549639699210747
   PubMed Web of Science ®Google Scholar
• HärtterS.WetzelH.HammesE.TorkzadehM.HiemkeC.Nonlinear pharmacokinetics of fluvoxamine and gender differences.Ther Drug Monit.1998204464499712472
   PubMed Web of Science ®Google Scholar
• KasperS.DötschM.KickH.VieiraA.MoIIerHJ.Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects.Eur Neuropsychopharmacol.1993313218471827
   PubMedGoogle Scholar
• GerstenbergG.AoshimaT.FukasawaT.et al.Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.Psychopharmacology.200316744344812682708
   PubMed Web of Science ®Google Scholar
• ReisbyN.GramLF.BechP.et al.Imipramine: clinical effects and pharmacokinetic variability.Psychopharmacology.197754263272413143
   PubMed Web of Science ®Google Scholar
• GabrisG.BaumannP.Jonzier-PereyM.BosshartP.WoggonB.KüpferA. N-MethyIation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients.Biochem Pharmacol.198534409410
   Web of Science ®Google Scholar
• OtaniK.KanekoS.SasaH.KondoT.FukushimaY.Is there a therapeutic window for plasma concentration of mianserin plus desmethylmianserin?Hum Psychopharmacol Clin Exp.19916243248
   Web of Science ®Google Scholar
• MiharaK.OtaniK.TybringG.DahlML.BertilssonL.KanekoS.The CYP 2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients.J Clin Psychopharmacol.1997174674719408809
   PubMed Web of Science ®Google Scholar
• EapCB.YasuiN.KanekoS.BaumannP.PowellK.OtaniK.Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites.Ther Drug Monit.19992116617010217335
   PubMed Web of Science ®Google Scholar
• TimmerCJ.LohmannAAM.MinkCPA.Pharmacokinetic dose-proportionality study at steady state of mirtazapine from remeron tablets.Hum Psychopharmacol.199510S97S106
   Web of Science ®Google Scholar
• SchoerlinMP.MayersohnM.KornA.EggersH.Disposition kinetics of moclobemide, a monoamine oxidase A enzyme inhibitor: single and multiple dosing in normal subjects.Clin Pharmacol Ther.1987423954043665338
   PubMed Web of Science ®Google Scholar
• LundmarkJ.ThomsenIS.Fjord-LarsenT.et al.Paroxetine: pharmacokinetic and antidepressant effect in the elderly.Acta Psychiatr Scand.198980(suppI350)7680
   Web of Science ®Google Scholar
• SindrupSH.BresenK.GramLF.et al.The relationship between paroxetine and the sparteine oxidation polymorphism.Clin Pharmacol Ther.1992512782871531950
   PubMed Web of Science ®Google Scholar
• KayeCM.HaddockRE.LangleyPF.et al.A review of the metabolism and pharmacokinetics of paroxetine in man.Acta Psychiatr Scand.198980(suppI350)60752763860
   PubMed Web of Science ®Google Scholar
• PellizzoniC.PoggesiI.JørgensenNP.EdwardsDMF.PausE.Strolin BenedettiM.Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations.Biopharm Drug Dispos.1996176236338894119
   PubMed Web of Science ®Google Scholar
• LundmarkJ.ReisM.BengtssonF.Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting.Ther Drug Monit.20002244645410942186
   PubMed Web of Science ®Google Scholar
• AxelsonDA.PerelJM.BirmaherB.et al.Sertraline pharmacokinetics and dynamics in adolescents.J Am Acad Child Adolesc Psychiatry.2002411037104412218424
   PubMed Web of Science ®Google Scholar
• OtaniK.TybringG.MiharaK.et al.Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients.Eur J Clin Pharmacol.1998533473499516035
   PubMed Web of Science ®Google Scholar
• MiharaK.KondoT.SuzukiA.et al.Effects of genetic polymorphism of CYP 1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients.Pharmacol Toxicol.20018826727011393588
   PubMedGoogle Scholar
• CournoyerG.De MontignyC.OuelletteJ.et al.A comparative doubleblind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade.J Clin Psychopharmacol.198773853933323262
   PubMed Web of Science ®Google Scholar
• EapCB.BenderS.GastparM.et al.Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP 2D6-, CYP 2C19- and CYP 3A4/5-phenotyped patients.Ther Drug Monit.20002220921410774635
   PubMed Web of Science ®Google Scholar
• TroySM.ParkerVD.FruncïIIoRJ.ChiangST.The pharmacokinetics of venlafaxine when given in a twice-daily regimen.J Clin Pharmacol.1995354044097650231
   PubMed Web of Science ®Google Scholar
• ReisM.LundmarkJ.BjorkH.BengtssonF.Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.Ther Drug Monit.20022454555312142641
   PubMed Web of Science ®Google Scholar
• Müller-OerlinghausenB.RütherE.Clinical profile and serum concentration of viloxazine as compared to amitriptyline.Pharmakopsychiatr Neuropsychopharmakol.197912321337386390
   PubMedGoogle Scholar
• PedersenOL.GramLF.KristensenCB.et al.Overdosage of antidepressants: clinical and pharmacokinetic aspects.Eur J Clin Pharmacol.1982235135217160420
   PubMed Web of Science ®Google Scholar
• PreskornS.JerkovichGS.Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring.J Clin Psychopharmacol.19901088952140373
   PubMed Web of Science ®Google Scholar
• BjerkenstedtL.FlycktL.OverøKF.LingjaerdeO.Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels.Eur J Clin Pharmacol.1985285535573899675
   PubMed Web of Science ®Google Scholar
• LeinonenE.LepolaU.KoponenH.KinnunenI.The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method.Ther Drug Monit.1996181111178721271
   PubMed Web of Science ®Google Scholar
• JonassonB.SaldeenT.Citalopram in fatal poisoning cases.Forensic Sci int.20021261611955823
   PubMed Web of Science ®Google Scholar
• Gex-FabryM.Balant-GorgiaAE.BalantLP.Clomipramine concentration as a predictor of delayed response: a naturalistic study.Eur J Clin Pharmacol.19995489590210192748
   PubMed Web of Science ®Google Scholar
• MavissakalianMR.JonesB.OlsonS.PerelJM.Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.J Clin Psychopharmacol.1990102612682286699
   PubMed Web of Science ®Google Scholar
• MclntyreIM.KingCV.CordnerSM.DrummerOH.Postmortem clomipramine: therapeutic or toxic concentrations?J Forensic Sci.1994394864938195760
   PubMed Web of Science ®Google Scholar
• Rodriguez de la TorreB.DreherJ.Malevanyl.et al.Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.Ther Drug Monit.20012343544011477329
   PubMed Web of Science ®Google Scholar
• PreskornSH.FastGA.Tricyclic antidepressant-induced seizures and plasma drug concentration.J Clin Psychiatry.1992531601621592842
   PubMed Web of Science ®Google Scholar
• GoodnickPJ.Pharmacokinetic optimisation of therapy with newer antidepressants.Clin Pharmacokinet.1994273073307834966
   PubMed Web of Science ®Google Scholar
• MontgomerySA.MontgomeryDB.McAuleyR.RaniSJ.Mianserin plasma levels and differential clinical response in endogenous and reactive depression.Acta Psychiatr Beg.197878798812
   PubMedGoogle Scholar
• IsacssonG.HolmgrenP.DruidH.BergmanU.The utilization of antidepressants―a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994.Acta Psychiatr Scand.199796941009272192
   PubMed Web of Science ®Google Scholar
• TïmmerCJ.SitsenJMA.DelbressineLP.Clinical pharmacokinetics of mirtazapine.Clin Pharmacokinet.20003846147410885584
   PubMed Web of Science ®Google Scholar
• VelazquezC.CarlsonA.StokesKA.LeikinJB.Relative safety of mirtazapine overdose.Vet Hum Toxicol.20014334234411757992
   PubMedGoogle Scholar
• FritzeJ.LauxG.SoficE.et al.Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines.Psychopharmacology.1989992522562508163
   PubMed Web of Science ®Google Scholar
• Gex-FabryM.Balant-GorgiaAE.BalantLP.Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide.Ther Drug Monit.19951739467725375
   PubMed Web of Science ®Google Scholar
• BaptistaT.TeneudL.ContrerasQ.et al.Lithium and body weight gain.Pharmacopsychiatry.19952835447624385
   PubMed Web of Science ®Google Scholar
• ÅsbergM.CronholmB.SjöqvistF.TuckD.Correlation of subjective side effects with plasma concentrations of nortriptyline.BMJ.1970418215470429
   PubMed Web of Science ®Google Scholar
• TaskerTCG.KayeCM.ZussmanBD.LinkCGG.Paroxetine plasma levels: lack of correlation with efficacy or adverse events.Acta Psychiatr Scand.198980(suppI350)152155
   Web of Science ®Google Scholar
• OhmanD.NorlanderB.PetersonC.BengtssonF.Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC.Ther Drug Monit.200123273411206039
   PubMed Web of Science ®Google Scholar
• MilnerDA.HallM.DavisGG.BrissieRM.RobinsonCA.Fatal multiple drug intoxication following acute sertraline use.J Anal Toxicol.1998225455489788533
   PubMed Web of Science ®Google Scholar
• BurkeMJ.PreskornSH.Therapeutic drug monitoring of antidepressants―cost implications and relevance to clinical practice.Clin Pharmacokinet.19993714716510496302
   PubMed Web of Science ®Google Scholar
• IwersenS.SchmoldtA.One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites.J Anal Toxicol.1996203013048872238
   PubMed Web of Science ®Google Scholar
• MonteleoneP.GnocchiG.DelrioG.Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study.J Clin Psychopharmacol.198992842872768543
   PubMed Web of Science ®Google Scholar
• GoeringerKE.RaymonL.ChristianGD.LoganBK.Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases.J Forensic Sci.20004563364810855970
   PubMed Web of Science ®Google Scholar
• VeefkindAH.HaffmansPMJ.HoencampE.Venlafaxine serum levels and CYP 2D6 genotype.Ther Drug Monit.20002220220810774634
   PubMed Web of Science ®Google Scholar
• LevineB.JenkinsAJ.QueenM.JuferR.SmialekJE.Distribution of venlafaxine in three postmortem cases.J Anal Toxicol.1996205025058889688
   PubMed Web of Science ®Google Scholar
• NormanTR.BurrowsGD.DaviesBM.MaguireKP.WurmJM.Viloxazine plasma concentrations and clinical response.J Affect Disord.198021571646210721
   PubMed Web of Science ®Google Scholar
• AltamuraAC.MauriMC.GuercettiG.Age, therapeutic “milieu” and clinical outcome in depressive patients treated with viloxazine: a study with plasma levels.Prog Neuropsychopharmacol Biol Psychiatry.19861067753704174
   PubMed Web of Science ®Google Scholar
• FalcyM.Riboulet-DelmasG.EfthymiouML.[Acute poisoning by viloxazine chlorhydrate taken by itself].Encéphale.19839137144
   PubMedGoogle Scholar
• McLeodDR.Hoehn-SaricR.PorgesSW.KowalskiPA.ClarkCM.Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder.J Clin Psychopharmacol.20002061562111106132
   PubMed Web of Science ®Google Scholar
• BaumannP.Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.Clin Pharmacokinet.1996314444698968657
   PubMed Web of Science ®Google Scholar
• RasmussenBB.BresenK.Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?Ther Drug Monit.20002214315410774624
   PubMed Web of Science ®Google Scholar
• BaumannP.KahnJM.Les médicaments génériques: quels sont les problèmes et d'où viennent-ils?Med Hyg.200361879884
   Google Scholar
• SajbelTA.CarterGW.WileyRB.Converting patients from brand-name clozapine to generic clozapine.Ann Pharmacother.20013528128411261523
   PubMed Web of Science ®Google Scholar
• MeredithPA.Generic drugs―therapeutic equivalence.Drug Safety.1996152332428905248
   PubMed Web of Science ®Google Scholar
• TseG.ThompsonD.ProcyshynRM.Generic clozapine: a cost-saving alternative to brand name clozapine?PharmacoEconomics.20032111112484800
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn.Pediatrics.200010588088710742343
   PubMed Web of Science ®Google Scholar
• BurtVK.SuriR.AltshulerL.StoweZ.HendrickVC.MunteanE.The use of psychotropic medications during breast-feeding.Am J Psychiatry.20011581001100911431219
   PubMed Web of Science ®Google Scholar
• ChaudronLH.JeffersonJW.Mood stabilizers during breastfeeding. A review.J Clin Psychiatry.200161799010732654
   PubMed Web of Science ®Google Scholar
• LlewellynA.StoweZN.Psychotropic medications in lactation.J Clin Psychiatry.199859(suppl 2)41529559759
   PubMed Web of Science ®Google Scholar
• ErnstCL.GoldbergJF.The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics.J Clin Psychiatry.200263(suppl 4)425511913676
   PubMed Web of Science ®Google Scholar
• European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on dose response information to support drug registration. 1995. Available at: www.emea.eu.int/pdfs/human/ich/037895en.pdf.XX.2005 6 Accessed 16 XXXXXX
   Google Scholar
• BertilssonL.DahlML.Polymorphic drug oxidationXX.relevance to the treatment of psychiatric disorders.CNS Drugs.19965200223
   Web of Science ®Google Scholar
• EnsomMHH.ChangTKH.PatelP.Pharmacogenetics―the therapeutic drug monitoring of the future?Clin Pharmacokinet.20014078380211735602
   PubMed Web of Science ®Google Scholar
• VuilleF.AmeyM.BaumannP.Use of plasma level monitoring of antidepressants in clinical practice―towards an analysis of clinical utility.Pharmacopsychiatry.1991241901951812496
   PubMed Web of Science ®Google Scholar
• KoutsilieriE.SchellerC.ter MeulenV.RiedererP.Monoamine oxidase inhibition and CNS immunodeficiency infection.Neurotoxicology.20042526727014697901
   PubMed Web of Science ®Google Scholar
• BrockmollerJ.KirchheinerJ.SchmiderJ.et al.The impact of the CYP 2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.Clin Pharmacol Ther.20027243845212386646
   PubMed Web of Science ®Google Scholar
• BengtssonF.Therapeutic drug monitoring of psychotropic drugs TDM “nouveau.”Ther Drug Monit.20042614515115228155
   PubMed Web of Science ®Google Scholar
• BondyB.ZillP.Psychopharmacogenetics―a challenge for pharmacotherapy in psychiatry.World J Biol Psychiatry.2001217818312587146
   PubMedGoogle Scholar